O Shaughnessy Asset Management LLC Has $4.94 Million Holdings in Bausch Health Companies Inc. (NYSE:BHC)

O Shaughnessy Asset Management LLC increased its holdings in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 989.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 611,890 shares of the company's stock after purchasing an additional 555,709 shares during the period. O Shaughnessy Asset Management LLC owned approximately 0.17% of Bausch Health Companies worth $4,940,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its position in Bausch Health Companies by 3.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,269,478 shares of the company's stock worth $10,373,000 after buying an additional 42,539 shares during the period. Cerity Partners LLC grew its stake in shares of Bausch Health Companies by 14.4% in the third quarter. Cerity Partners LLC now owns 79,290 shares of the company's stock worth $647,000 after acquiring an additional 9,978 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Bausch Health Companies by 26.5% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 76,807 shares of the company's stock worth $628,000 after acquiring an additional 16,101 shares during the period. Verition Fund Management LLC acquired a new position in Bausch Health Companies during the 3rd quarter valued at $808,000. Finally, Cinctive Capital Management LP boosted its holdings in Bausch Health Companies by 25.9% in the 3rd quarter. Cinctive Capital Management LP now owns 83,710 shares of the company's stock valued at $683,000 after purchasing an additional 17,233 shares during the period. Institutional investors and hedge funds own 78.65% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BHC shares. Jefferies Financial Group restated a "hold" rating and set a $8.00 price objective (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada lowered their price target on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a research note on Monday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Bausch Health Companies has a consensus rating of "Hold" and an average target price of $7.17.

Bausch Health Companies Trading Down 1.4 %

NYSE BHC traded down $0.08 on Monday, reaching $5.26. The company's stock had a trading volume of 4,043,954 shares, compared to its average volume of 2,737,684. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $10.46. The firm has a market cap of $1.93 billion, a PE ratio of -43.79, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43. The business has a 50-day moving average price of $6.86 and a 200 day moving average price of $7.67.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. Analysts anticipate that Bausch Health Companies Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.